Introdução A síndrome do QT longo tipo 3 (SQTL3) é uma canalopatia de alta letalidade. Está associada ao déficit de fechamento dos canais tardios de sódio, decorrentes de mutações no gene SCN5A , de padrão autossômico dominante, responsável por 7-10% de todas as síndromes do QT longo (SQTL). A apresentação inicial pode ter amplo espectro, desde assintomáticos, até morte súbita no primeiro ano de vida. A adição do bloqueador do canal de sódio classe IB (mexiletina) ao propranolol ou nadolol [...] Introdução A síndrome do QT longo tipo 3 (SQTL3) é uma canalopatia de alta letalidade. Está associada ao déficit de fechamento dos canais tardios de sódio, decorrentes de mutações no gene SCN5A , de padrão autossômico dominante, responsável por 7-10% de todas as síndromes do QT longo (SQTL). A apresentação inicial pode ter amplo espectro, desde assintomáticos, até morte súbita no primeiro ano de vida. A adição do bloqueador do canal de sódio classe IB (mexiletina) ao propranolol ou nadolol
Brugada Syndrome (BrS) typically manifests with a dynamic type 1 Brugada pattern (Br1ECGp) that depends on the dominance of the sympathetic or parasympathetic nervous system. This pattern is more prominent during activities that stimulate the vagus nerve, such as sleeping and after meals. By conducting the tilt table test and adding high precordial leads to the standard protocol, it is possible to provoke sympathetic or parasympathetic responses, providing valuable information. This was an observational, cross-sectional and hypothesis-generating pilot study. The tilt table test was performed with high precordial leads on three Brugada patients to assess the Br1ECGp during the test. The ECG features were continuously recorded to analyze variations during all phases of the test. The first patient exhibited a significant Br1ECGp that disappeared during the upward phase of the tilt table test and reappeared during the recovery phase. The second patient had a Br1ECGp in three leads that persisted during both the upward and recovery phases of the tilt table test. The third patient displayed a Br1ECGp in three leads, which was maintained during the upward phase in two leads and recovered during the recovery phase. The third patient was the only one to experience cardioinhibitory syncope. This study provided insights into the dynamics of the Br1ECGp during the tilt table test when enhanced by high precordial leads. It reaffirmed that the Brugada ECG pattern is influenced by sympathetic or parasympathetic dominance.
Background/Objectives: The Type 1 Brugada ECG pattern (BrP1) fluctuates according to autonomic influences. Tilt table testing induces changes in both sympathetic and parasympathetic activity. It may provide insights into the dynamic behavior of BrP1 when combined with high-precordial lead placement. However, the clinical significance of BrP1 variability during tilt table testing remains poorly defined. Methods: This cross-sectional study evaluated patients with confirmed Brugada syndrome who underwent tilt table testing with continuous ECG monitoring using high-precordial leads. BrP1 behavior was assessed during predefined phases: baseline supine position, orthostatic tilt, nitrate administration, recovery, and syncope when present. Subsequently, clinical characteristics and test results were analyzed for associations with dynamic BrP1 expression. Results: Forty-four patients (mean age 49 years; 72.7% men) were included. Thirty-five patients (79.5%) had a spontaneous type 1 Brugada ECG pattern, and nine (20.5%) had a drug-induced pattern. BrP1 expression varied dynamically/heterogeneously during tilt table testing. No patient without BrP1 at admission developed the pattern during tilt phases. Thirty patients (68.1%) remained negative throughout testing, while five lost the pattern during the test (11.3%), and nine (20.4%) showed persistent BrP1 in all phases. Persistent BrP1 was associated with more frequent presumed arrhythmic syncope and implantable cardioverter defibrillator implantation (p < 0.05). No atrial or ventricular arrhythmias or device-related complications occurred. Conclusions: Tilt table testing with high precordial leads does not unmask BrP1 and should not be used as a diagnostic provocation tool. However, it allows for the characterization of autonomic modulation and phenotypic stability in Brugada syndrome. Any potential prognostic relevance of dynamic BrP1 behavior remains speculative and requires evaluation in adequately powered prospective studies.